Shire, the Irish drug company that keeps the headquarters of its Human Genetic Therapies unit in Massachusetts, told the Boston Globe yesterday that the firm plans to invest $460 million in its new campus in Lexington, MA, and hire 750 new workers in the Bay State over an eight-year period—increasing the scope of its plans announced last year to invest $394 million and add 680 employees in the state during that span of time. Sylvie Gregoire, president of Shire’s HGT business, talked to Xconomy late last year about the reasons for the expansion.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
